JP2020524149A5 - - Google Patents

Download PDF

Info

Publication number
JP2020524149A5
JP2020524149A5 JP2019569878A JP2019569878A JP2020524149A5 JP 2020524149 A5 JP2020524149 A5 JP 2020524149A5 JP 2019569878 A JP2019569878 A JP 2019569878A JP 2019569878 A JP2019569878 A JP 2019569878A JP 2020524149 A5 JP2020524149 A5 JP 2020524149A5
Authority
JP
Japan
Prior art keywords
agent
treg
breg
cancer
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019569878A
Other languages
English (en)
Japanese (ja)
Other versions
JP7843113B2 (ja
JP2020524149A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/038490 external-priority patent/WO2018236995A2/en
Publication of JP2020524149A publication Critical patent/JP2020524149A/ja
Publication of JP2020524149A5 publication Critical patent/JP2020524149A5/ja
Application granted granted Critical
Publication of JP7843113B2 publication Critical patent/JP7843113B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019569878A 2017-06-20 2018-06-20 Ａｐｒｉｌ－ｔａｃｉ間相互作用のモジュレーターを用いた制御性ｔ細胞、制御性ｂ細胞、及び免疫応答の調節方法 Active JP7843113B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762522167P 2017-06-20 2017-06-20
US62/522,167 2017-06-20
US201762573264P 2017-10-17 2017-10-17
US62/573,264 2017-10-17
US201862677265P 2018-05-29 2018-05-29
US62/677,265 2018-05-29
PCT/US2018/038490 WO2018236995A2 (en) 2017-06-20 2018-06-20 Methods for modulating regulatory t cells, regulatory b cells, and immune responses using modulators of the april-taci interaction

Publications (3)

Publication Number Publication Date
JP2020524149A JP2020524149A (ja) 2020-08-13
JP2020524149A5 true JP2020524149A5 (https=) 2021-07-29
JP7843113B2 JP7843113B2 (ja) 2026-04-09

Family

ID=64735842

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019569878A Active JP7843113B2 (ja) 2017-06-20 2018-06-20 Ａｐｒｉｌ－ｔａｃｉ間相互作用のモジュレーターを用いた制御性ｔ細胞、制御性ｂ細胞、及び免疫応答の調節方法

Country Status (7)

Country Link
US (1) US12005073B2 (https=)
EP (1) EP3642243A4 (https=)
JP (1) JP7843113B2 (https=)
CN (1) CN110945030A (https=)
AU (1) AU2018289493B2 (https=)
CA (1) CA3064632A1 (https=)
WO (1) WO2018236995A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11435370B2 (en) * 2017-01-16 2022-09-06 Shimadzu Corporation Data analying device and program for data analysis
EP3642243A4 (en) 2017-06-20 2021-04-28 Dana-Farber Cancer Institute, Inc. METHOD OF MODULATING REGULATORY T-CELLS, REGULATORY B-CELLS AND IMMUNE RESPONSIBILITIES USING MODULATORS OF APRIL-TACI INTERACTION
EP3887548A1 (en) * 2018-11-30 2021-10-06 GBG Forschungs GmbH Method for predicting the response to cancer immunotherapy in cancer patients
KR20220016188A (ko) * 2019-05-31 2022-02-08 메디뮨 엘엘씨 병용 요법
JP7748393B2 (ja) 2020-05-08 2025-10-02 アルパイン イミューン サイエンシズ インコーポレイテッド Ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法
US20230310500A1 (en) * 2020-09-03 2023-10-05 Techno Craft Corporation Ltd. Use of Immune Killer Cell Against Circulating Tumor Cells in Solid Tumor Treatment
CN113368262A (zh) * 2020-09-03 2021-09-10 上海易慕峰生物科技有限公司 通过实体肿瘤转移动物模型获取中间结果的方法
US20230250042A1 (en) * 2020-09-29 2023-08-10 Purdue Research Foundation Curcusone diterpenoids and uses thereof
CN113278619B (zh) * 2021-07-19 2021-10-15 广东省农业科学院动物科学研究所 双sgRNA、基因敲除载体、基因敲除STING基因的猪成纤维细胞系及其构建方法
CN114147343B (zh) * 2021-12-08 2024-08-16 西安中科微精光子科技股份有限公司 一种激光加工方法、系统及计算机存储介质
CN118126196B (zh) * 2024-03-06 2024-08-16 中国医学科学院基础医学研究所 一种具有包含taci融合蛋白的基因工程化外泌体及其制备方法和应用
CN120843525B (zh) * 2025-09-23 2025-12-09 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 特异结合人april的中和核酸适体及其在抑制抗体分泌中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086018A1 (en) * 2000-05-12 2002-07-04 Theill Lars Eyde Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI
US20040259247A1 (en) * 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
CN101323643B (zh) * 2007-06-15 2010-12-01 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白
WO2010075249A2 (en) * 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP2488200A4 (en) 2009-10-14 2013-06-12 Merck Sharp & Dohme APRIL ANTAGONISTS AND METHOD FOR THEIR USE
CN102585016B (zh) 2012-03-06 2014-06-04 江苏健德生物药业有限公司 一种可同时抑制t、b淋巴细胞功能的免疫融合蛋白、其制备方法及其应用
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
EP3642243A4 (en) 2017-06-20 2021-04-28 Dana-Farber Cancer Institute, Inc. METHOD OF MODULATING REGULATORY T-CELLS, REGULATORY B-CELLS AND IMMUNE RESPONSIBILITIES USING MODULATORS OF APRIL-TACI INTERACTION

Similar Documents

Publication Publication Date Title
JP2020524149A5 (https=)
AU2023203601B2 (en) Ex vivo bite-activated T cells
Stein et al. Blinatumomab for acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation
CN104427992B (zh) 生物标志物及使用溶瘤病毒和免疫调节剂的组合疗法
JP2022513685A (ja) 養子細胞療法を用いた処置のための方法
US20220169694A1 (en) Chimeric antigen receptor t cell therapy
JP2021521137A (ja) 腫瘍微小環境の特性を使用するキメラ受容体ｔ細胞治療
JP2021524240A (ja) 二重特異性抗体の組成物及びその使用方法
JP2016509582A5 (https=)
Michelakos et al. B7-H3 targeted antibody-based immunotherapy of malignant diseases
US20240110230A1 (en) Biomarkers for cancer treatment
US20260109766A1 (en) Lag-3 antagonist therapy for melanoma
CN114206346A (zh) 施用嵌合抗原受体免疫疗法的方法
US20250313855A1 (en) Chimeric antigen receptor t cell therapy
US20210252036A1 (en) Methods of treating cancer by inhibiting ubiquitin conjugating enzyme e2 k (ube2k)
US20240252633A1 (en) Methods of treating cancer with cd-40 agonists
Stock et al. Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma
US20240158869A1 (en) Factors for optimizing immunotherapy
US20250290154A1 (en) Predictive markers for immunotherapy
US20250161361A1 (en) Factors for optimizing immunotherapy efficacy
Gross et al. CD19× CD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease
Miyahira et al. The 29th Annual Prostate Cancer Foundation Scientific Retreat Report
HK40115765A (zh) 从免疫疗法预测不良事件
HK40054961A (en) Methods of treating cancer by inhibiting ubiquitin conjugating enzyme e2 k (ube2k)
HK40096812A (zh) 离体bite激活的t细胞